Wissenschaftlicher Leiter und CEO der HUB Prof. Dr. Thomas Illig Prof. Dr. Thomas Illig +49 511 5350 - 8450 Illig.Thomas[a]mh-hannover.de Background Since January 2012 Thomas Illig is director of the Hannover

Immunology Research Centre of Excellence at Koç University, Istanbul, Turkey Since 2022 Co-founder and CEO, Allogenetics GmbH (Biotech) Download PDF RESEARCH His research aims to prevent transplant rejection

Research, Merck Group, Darmstadt Dr. Marcus Furch (1996-1999 Dr. rer. nat. in the Manstein group) CEO, Rodos BioTarget GmbH, Frankfurt Dr. Heike Nöthe (1998-2001 Dr. rer. nat. in the Manstein group) Editor

Regensburg 1986 - 1991 Study of biology, University of Regensburg Professional Experience Since 01/2012 CEO and scientific head of Hannover Unified Biobank (HUB), Hannover Medical School 01/2011 - 12/2011 Head

Tissues 04.02.2010, Special lecture (6.30 pm, s.t., lecture hall N) Peter C. Johnson, MD, President and CEO Scintellix and Chief Editor 'Tissue Engineering', Raleigh, North Carolina/USA: Strategic Directions

program through larger pivotal trials and toward market approval," said IMTTS Director and Cardior CEO Professor Thum. The lead compound, CDR123L, is a synthetic antisense oligonucleotide and a selective